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Introduction: The polymer PEI-MP (polyethyleneimine, functionalised with methylphosphonate 
groups) was initially synthesized for palliative therapy of bone metastases after convenient 
radiolabelling. However, in biodistribution studies performed with this polymer radiolabelled with 
different radionuclides, was obvious a higher uptake by the bladder wall, that might demonstrate 
a certain selectivity to bladder cells, and so, to bladder cancer cells. The aim of this study was 
to evaluate the efficacy of PEI-MP radiolabeled with 99mTc for imaging diagnosis and follow up of 
bladder cancer.  
Material and Methods: Because PEI-MP should act as a carrier with high selectivity to bladder 
cancer cells and not to induce any arm, it was analysed the cytotoxicity in bladder carcinoma 
cell line (CRL-1472) using the MTT test and flow cytometry. The radiochemical purity of 99mTc-
PEI-MP was achieved using ascending microchromatography. Then, cellular uptake studies 
were performed using 99mTc-PEI-MP and Na99mTcO4 as control. Cell samples were collected 
during four hours, centrifuged to separate supernatant and pellet. Subsequently, the 
 
  
  
  
 
 
 
 
 
radioactivity of each portion was counted to determine percentage of uptake. The in vivo studies 
were performed using four groups of
 
Balb/c nu/nu mice: two normal groups injected with 
Na99mTcO4 and 99mTc-PEI-MP and two with bladder carcinoma xenotransplants injected with the 
same complexes. Radiopharmaceuticals were administered by an intravenous injection in the 
tail vein (22-37MBq), with the animal anesthetized and previously placed on a gamma camera 
detector. Subsequently, were acquired dynamic and static images for 2 and 4 hours, and mice 
were euthanized and organ samples where weighted and counted in a well-counter to obtain 
percentage injected activity per gram of organ (%ID/g).  
Results: The MTT assay and flow cytometry tests showed that PEI-MP is not cytotoxic. The 
radiochemical purity of 99mTc-PEI-MP was ≥85%. The uptake studies demonstrated that the 
uptake was higher for 99mTc-PEI-MP in relation to their control. Biodistribution with 99mTc-PEI-
MP showed that the excretion of this complex occurs primarily through the renal system. The 
tumour/muscle ratio was superior to 1,2.   
Conclusions: 99mTc-PEI-MP seems to be optimal for diagnosis and follow up. 
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